Erasca Ventures

Erasca Ventures is a corporate venture capital firm established in March 2021 as a wholly-owned subsidiary of Erasca, Inc., a clinical-stage precision oncology company headquartered in San Diego, California. The firm focuses on making equity investments in early-stage biotechnology companies that are aligned with Erasca's mission to erase cancer. Erasca Ventures aims to support innovative companies developing therapies targeting the RAS/MAPK pathway, a key driver in various cancers.

The investment strategy of Erasca Ventures is to identify and support companies with promising therapeutic candidates that complement Erasca's existing pipeline. By investing in these companies, Erasca Ventures seeks to accelerate the development of novel oncology treatments and expand the reach of Erasca's mission. The firm is particularly interested in companies that are developing therapies targeting the RAS/MAPK pathway, which is implicated in approximately five million new cancer cases globally each year.

Erasca Ventures operates with a collaborative approach, leveraging the resources and expertise of its parent company, Erasca, Inc., to provide strategic guidance and support to its portfolio companies. This partnership aims to enhance the development and commercialization of innovative oncology therapies, ultimately contributing to the advancement of cancer treatment and the achievement of Erasca's goal to erase cancer.